RemeGen Focused on Growing Domestic Business
Shaojing Tong, CFO at Chinese biotech firm RemeGen, discusses the company's first quarter results and shares his confidence in growth in the domestic market. The company's stock has outperformed all of its peers in the MSCI China Healthcare Index since the start of the year. (Source: Bloomberg)
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.